Pfizer Exceeds Q1 Revenue and EPS Estimates, Reaffirms Full-Year Outlook
PFE sits 20% above its 52-week low of $21.97.
Summary
Pfizer reported stronger-than-expected first-quarter results, with revenue reaching $14.45 billion, surpassing analyst estimates of $13.79 billion, and adjusted EPS of $0.75, beating the $0.72 consensus. This positive performance was primarily driven by robust product growth from key drugs such as Padcev and Eliquis. The company also reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted EPS guidance of $2.80 to $3.00, which was previously reported earlier today. The Q1 beat, combined with the reiterated full-year outlook, indicates operational resilience and confidence in its core business, despite anticipated headwinds from generic and biosimilar competition. Traders will focus on sustained product momentum and the company's strategy to mitigate patent cliff impacts.
At the time of this announcement, PFE was trading at $26.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $149.6B. The 52-week trading range was $21.97 to $28.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.